Real-World Functional and Anatomic Outcomes With Aflibercept 8.0 mg in Patients With Diabetic Macular Edema.

ABSTRACT: Purpose: To assess clinical outcomes in diabetic macular edema (DME) patients treated with high-dose aflibercept 8.0 mg (HDA), focusing on treatment intervals, anatomic changes, and best-corrected visual acuity (BCVA). Methods: This retrospective, single-center study included 67 DME patients (100 eyes) treated at Cole Eye Institute between August 2023 and November 2024. All patients received at least 3 HDA injections, with a true loading dose defined as 3 initial injections given ≤ 5 weeks apart. The primary outcome was proportion of eyes for which minimum ≥ 7-week treatment intervals were maintained. Secondary outcomes included changes in BCVA, central subfield thickness (CST), and macular fluid status. Results: Loading dose was completed in 73 eyes (73%) and not comp

SUBMITTER: Barbosa GCS 

PROVIDER: S-EPMC12496451 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature